Stockwinners Market Radar for August 16, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:05 EDT Cathie Wood's ARK Investment bought 2.69M shares of Archer Aviation today

19:08 EDT UPS exec sells $3.92M in common stock - In a regulatory filing, UPS disclosed that its President of U.S. Operations sold 22.8K shares of common stock on August 16th in a total transaction size of $3.92M.

18:47 EDT Synaptics exec Awsare sells 7,669 common shares - In a regulatory filing, Synaptics senior VP Saleel Awsare disclosed the sale of 7,669 common shares of the company on August 14 at a price of $91.1625 per share.

17:49 EDT Lovesac down 7% at $22.00 afterhours following restatement of financials

17:35 EDT Epic Games 'empowers' developers with expansion of crossplay tools - Epic's Rajen Kishna blogged earlier on Wednesday: "In June 2022, Epic Online Services introduced a free PC crossplay overlay to empower developers to connect their games and communities across multiple PC stores. Today, we are expanding this crossplay overlay with initial support for games on Microsoft Xbox (MSFT), Nintendo Switch (NTDOY), and Sony PlayStation (SONY) while enhancing its capabilities across all supported platforms. The crossplay overlay offers a ubiquitous way to authenticate players, streamline friend management, and provide game invite and joinability functionality that's designed to be compliant with native platform requirements. Crossplay enables bigger games, bigger audiences, and growth for the global games industry. With the added support for the major console platforms, Epic Online Services now enables you to connect more players with a single overlay."...The fly notes that TenCent (TCEHY) is a percentage owner of Epic games along with Jim Sweeney who holds more than 50% of the company. Other publicly traded companies in the space include Meta Platforms (META), Pinterest (PINS), Snap (SNAP), Alphabet (GOOG, GOOGL) and X (TWTR). Reference Link

17:22 EDT Digital World Acquisition to postpone general meeting of shareholders - In a regulatory filing, the company stated: "On August 16, 2023, Digital World Acquisition Corp., a Delaware corporation determined to postpone the Company's extraordinary general meeting of its shareholders from the previously scheduled date of Thursday, August 17, 2023. The Special Meeting will now be held on September 5, 2023, at 10:00 a.m. Eastern Time. There is no change to the location, the record date, the purpose or any of the proposals to be acted upon at the Special Meeting."

17:17 EDT Chesapeake to replace Mercury Systems in S&P 400 at open on 8/21

17:01 EDT Cisco sees Q1 gross margin 65%-66% - Sees Q1 tax rate 19%. Sees FY24 tax rate 19%. Says had a very strong quarter and fiscal year. Says important to shareholders that the company commits to and delivers operating leverage in the profit and loss statement. Says significant improvement in renewal rates on the software side. Says software renewals in enterprise networking space will be meaningful in FY24. Comments and guidance taken from Q4 earnings conference call.

16:39 EDT Precigen director buys $998K in common stock - In a regulatory filing, Precigen disclosed that its director Fred Hassan bought 570K shares of common stock on August 14th in a total transaction size of $998K.

16:37 EDT SeaChange says has $131M of NOLs at Jan-end, board adopts tax plan to preserve - SeaChange International announced that its Board of Directors adopted a Tax Benefits Preservation Plan, dated August 16, by and between the Company and Computershare Trust Company as rights agent, that is intended to protect and preserve the ability of the Company to use its existing net operating loss carryforwards and certain other tax assets to reduce the Company's potential future federal income tax obligations. As of January 31 the Company had United States federal NOLs of approximately $131M. The Plan is similar to the Company's previous Tax Benefits Preservation Plan, as amended, dated March 4, 2019, by and between the Company and Computershare as rights agent, which expired on March 4, 2022. The Company's use of its NOLs could be substantially limited if the Company experiences an "ownership change" as defined in Section 382 of the Internal Revenue Code, as amended...In general, an ownership change would occur if one or more of the Company's stockholders who are deemed to be "5% shareholders" under Section 382 collectively increase their aggregate ownership of the Company's common stock by more than 50 percentage points over the lowest percentage owned by such stockholders at any time within a rolling three-year period.

16:35 EDT Powerbridge receives Nasdaq notice of non-compliance - Powerbridge Technologies announced that it has received a notification letter from the Nasdaq Stock Market dated August 11, notifying the company that it is not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq.

16:33 EDT Toast CEO Comparato sells 58,000 class A shares - In a regulatory filing, Toast CEO Christopher Comparato disclosed the sale of 58,000 class A common shares of the company on August 15 at a price of $23.272 per share.

16:32 EDT Corporacion America Airport reports July passenger traffic up 22.1% y/y - Corporacion America Airports reported a 22.1% year-on-year increase in passenger traffic in July 2023, reaching 96.3% of July 2019 levels. Total passenger traffic grew 22.1% compared to the same month of 2022, supported by the ongoing recovery in travel demand after the Covid-19 pandemic and the gradual resumption of routes and frequencies across all countries of operations. Overall passenger traffic reached 96.3% of July 2019 levels, down from 102.6% posted in June, with international passenger traffic surpassing pre-pandemic levels of July 2019 by 5.2%. Domestic traffic stood at 93.6% of July 2019.

16:31 EDT Chegg increases stock repurchase program by $200M - Chegg announced its board of directors has authorized an increase of $200M as part of its securities repurchase program. The program allows Chegg to buy back its common stock and/or convertible notes, through open market purchases, block trades and/or in privately negotiated transactions or pursuant to Rule 10b5-1 plans, in compliance with applicable securities laws and other legal requirements. In addition to this increased $200M securities repurchase authorization, Chegg has approximately $89M remaining from its previously announced $2B securities repurchase program. The timing, volume, and nature of any repurchases will be determined by Chegg's management, in consultation with the board's Finance Committee, based on its evaluation of the capital needs of the business, market conditions, applicable legal requirements, and other factors. The repurchase program has no expiration date and will continue until otherwise suspended, terminated, or modified at any time for any reason by our board of directors. Chegg currently expects to fund the repurchase program from its existing cash balance and future cash flows from operations.

16:20 EDT Immunovant CEO sells $2.2M in common stock - In a regulatory filing, Immunovant disclosed that its CEO Peter Salzmann sold 103K shares of common stock on August 14th in a total transaction size of $2.2M.

16:16 EDT Natural Alternatives International announces temporary plant closure - Natural Alternatives International announced a temporary closure of its new facility in Carlsbad, California, opened earlier this year to expand NAI's production and add high-speed powder blending and packaging to its manufacturing capabilities, with an initial objective of handling current and estimated orders from one of its largest customers. Due to this customer's efforts to rebalance supply and demand, it is temporarily ceasing purchases from Natural Alternatives. As a result, NAI has determined to temporarily close its new high-speed powder blending and packaging facility and has provided sixty days advance notice to most of the staff at that facility, who will be furloughed starting in early October and lasting until approximately December 31, 2023. NAI currently expects these economic factors will be short lived, and in order to influence furloughed employees to return, NAI will pay for the health insurance costs of all furloughed employees during the employee's furlough period, through December 31, 2023. NAI expects to begin shipping new orders to this customer during the first quarter of calendar 2024. Reduction of these anticipated orders and the closure of the facility is anticipated to have an adverse effect on our results of operations and financial condition primarily during the last calendar quarter of this year, and possibly into the early part of 2024.

16:15 EDT Cisco sees Q1 adjusted gross margin 65%-66% - Sees Q1 adjusted operating margin 34%-35%.

16:09 EDT Robinhood reports July assets under custody $94.5B, up 6% - Robinhood reported selected monthly operating data for July. Net cumulative funded accounts at the end of July were 23.2M, up approximately 50,000 from June. Monthly active users increased to 11M in July, up approximately 200,000 from June. Assets under custody at the end of July were $94.5B, up 6% from June. Net deposits were $1.4B in July, translating to a 19% annualized growth rate relative to June AUC. Over the last twelve months, net deposits were $16.8B, translating to an annual growth rate of 23% relative to July 2022 AUC. Trading volumes in July were higher for equities and crypto and lower for options compared to June 2023. Equity notional trading volumes were $69.2B. Options contracts traded were 106.1M. Crypto notional trading volumes were $3.4B. Margin balances at the end of July were $3.4B, up 3% from June. Cash sweep balances at the end of July were $12.7B, up $0.8B from the end of June.

16:09 EDT Alico appoints Bradley Heine CFO amid Del Vecchio departure - Alico announced the departure of Perry G. Del Vecchio as the Company's Chief Financial Officer, effective as of August 16 , and the hiring and appointment of Bradley Heine as his replacement, effective as of today, August 16. As the new Chief Financial Officer, principal financial officer, and principal accounting officer for Alico, Mr. Heine will be responsible for all corporate finance, treasury and accounting functions of the Company and will report directly to John Kiernan, the Company's President and Chief Executive Officer. "We are grateful for the service Perry has given to Alico over the past year and wish him well in his next endeavors," said Mr. Kiernan.

16:08 EDT Wolfspeed incurs $39.5M of factory startup costs in Q4 - "As part of expanding our production footprint to support expected growth, we are incurring significant factory start-up costs relating to facilities that we are constructing or expanding that have not yet started revenue generating production. These factory start-up costs have been and will be expensed as operating expenses in our statement of operations," the company said. "When a new facility begins revenue generating production, the operating costs of that facility that were previously expensed as start-up costs will instead be primarily reflected as part of the cost of production within the cost of revenue, net line item in our statement of operations. For example, our new silicon carbide device fabrication facility in Marcy, New York began revenue generating production at the end of fiscal 2023 and the costs of operating this facility going forward will be primarily reflected in cost of revenue, net in future periods. During the period when production begins, but before the facility is at its expected utilization level, we expect some of the costs to operate the facility will not be absorbed into the cost of inventory. The costs incurred to operate the facility in excess of the costs absorbed into inventory are referred to as underutilization costs and are expensed as incurred to cost of revenue, net. We expect that these costs will be substantial as we ramp up the facility to the expected utilization level. We incurred $39.5 million and $160.2 million of factory start-up costs for the fourth quarter and full fiscal year 2023, respectively, which accounted for a significant portion of our operating expenses. For the first quarter of fiscal 2024, we target our operating expenses to include approximately $8 million of factory start-up costs primarily in connection with our materials expansion efforts and our cost of revenue, net, to include approximately $37 million of underutilization costs primarily in connection with our new silicon carbide device fabrication facility in Marcy, New York."

15:45 EDT Hawaiian Electric gives up gains after WSJ report of restructuring talks

14:27 EDT Miromatrix rallies after NYU Langone touts engineered pig kidney transplant - Surgeons at NYU Langone Health have transplanted a genetically engineered pig kidney that continues to function well after 32 days in a man declared dead by neurologic criteria and maintained with a beating heart on ventilator support, the organization said in a statement. "This represents the longest period that a gene-edited pig kidney has functioned in a human, and the latest step toward the advent of an alternate, sustainable supply of organs for transplant," according to NYU Langone Health. Shares of Miromatrix Medical are up 13% to $1.49 following the announcement. The company has developed a perfusion technology platform for bioengineering organs. Reference Link

14:17 EDT North American rail traffic down 4.2% for the week ending August12 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending August 12. For this week, total U.S. weekly rail traffic was 472,498 carloads and intermodal units, down 4.2% compared with the same week last year. Total carloads for the week ending August 12 were 224,412 carloads, down 3% compared with the same week in 2022, while U.S. weekly intermodal volume was 248,086 containers and trailers, down 5.3% compared to 2022. Three of the 10 carload commodity groups posted an increase compared with the same week in 2022. They were motor vehicles and parts, up 1,534 carloads, to 14,945; petroleum and petroleum products, up 1,419 carloads, to 9,952; and miscellaneous carloads, up 695 carloads, to 9,281...North American rail volume for the week ending August 12, on 12 reporting U.S., Canadian and Mexican railroads totaled 329,821 carloads, down 0.7% compared with the same week last year, and 329,158 intermodal units, down 7.5% compared with last year. Total combined weekly rail traffic in North America was 658,979 carloads and intermodal units, down 4.2%. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific Kansas City (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), (GBX),Trinity Industries (TRN), FreightCar America (RAIL), Wabtec (WAB) and Rail Vision (RVSN). Reference Link

13:27 EDT Daniel Och says Rithm Capital deal substantially undervalus Sculptor Capital

12:50 EDT Mitek Systems receives noncompliance notice from Nasdaq - Mitek Systems reported that on August 14, 2023, it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 in a timely manner and that such matter serves as an additional basis for delisting the company's securities from Nasdaq. The Rule requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission. The company previously reported in its Form 12b-25 filed with the SEC on August 10, 2023 that the company was unable to file its Q3 Form 10-Q, May 10, 2023 that the company was unable to file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 and February 10, 2023 that the Company was unable to file its Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2022, in each case within the prescribed time period without unreasonable effort or expense. On June 20, 2023 the company timely requested a hearing before the Nasdaq Hearings Panel to appeal a determination by the Nasdaq Listing Qualifications Department to delist the company's securities due to the company's failure to timely file its Annual Report on Form 10-K for the period ended September 30, 2022 and its Q1 Form 10-Q and Q2 Form 10-Q, with the Securities and Exchange Commission and requested that the automatic stay of suspension be extended through the completion of the hearings process and the expiration of any additional extension period granted by the Panel following the hearing.

12:00 EDT Holley falls -14.8% - Holley is down -14.8%, or -$1.08 to $6.25.

12:00 EDT Progressive rises 9.2% - Progressive is up 9.2%, or $11.55 to $136.60.

12:00 EDT H&R Block rises 10.6% - H&R Block is up 10.6%, or $3.73 to $39.08.

11:57 EDT Nuvectis granted orphan status for cholangiocarcinoma treatment - The FDA granted Nuvectis Pharma orphan status for its treatment of cholangiocarcinoma. Reference Link

11:23 EDT TJX expects to continue to plan shrink flat in FY24

11:05 EDT TJX CEO: Q3 off to a great start - Comments taken from Q2 earnings conference call.

11:03 EDT South 8 Technologies reports strategic investment from Lockheed Martin Ventures - South 8 Technologies, a San Diego cleantech company, has closed a strategic investment with Lockheed Martin Ventures, the venture arm of Lockheed Martin, with participation from current South 8 investors LG Technology Ventures, Foothill Ventures and Anzu Partners.

10:42 EDT WeTrade Group Inc trading halted, volatility trading pause

10:33 EDT Caesars launches Caesars Palace Online Casino - Caesars Entertainment unveiled Caesars Palace Online Casino, an online casino app and desktop platform that ties online gaming to Caesars' customer loyalty program, Caesars Rewards, and leverages the entire network of more than 50 Caesars destinations throughout the United States and Canada. Those 21 and older in New Jersey, Pennsylvania, Michigan, West Virginia, and Ontario can now download the Caesars Palace Online Casino app on iOS and Android or visit caesarspalaceonline.com to enjoy a fully immersive casino-first experience with player rewards, exclusive games, and promotions.

10:25 EDT J.B. Hunt shares drop 2% to $195.68 as company presents at conference

10:21 EDT J.B. Hunt says 'just a wait and see on the economy in general'

10:18 EDT Pitney Bowes urges Stamps.com customers to switch to PitneyShip - The company said, "Dear Stamps.com customers, Don't stand for exorbitant price increases. Do you believe Auctane, who owns stamps.com, truly cares about your business? They recently raised their already high monthly price for their stamps.com service that you use. They also doubled the price of their ShipStation service for clients who wanted to access their existing carrier accounts. Customers are sharing their frustration as you can read here. We feel your pain. Enough is enough. Pitney Bowes helps our more than 750,000 small business clients remove the complexity of sending parcels and mail through our flagship PitneyShip software solution which prints shipping labels and stamps at discounted prices. We have been a partner of the United States Postal Service for more than a century and are guided by a core principle of doing the right thing, the right way. While we understand businesses need to raise prices from time to time, Pitney Bowes will never spring exorbitant price increases on our clients. In short, we believe we are a better partner. We want you to try us out, and if you do, we'll give you a chance to win a $10,000 cash gift to help grow your business.* Any business that signs up for a 30-day free trial of our superior PitneyShip solution - already priced 25 percent less than stamps.com - between now and September 14, will be entered into a drawing to receive one of five $10,000 cash gifts. While Stamps.com raises prices that hurt your business, Pitney Bowes wants to work with you to help grow your business."

10:13 EDT Amazon Music Unlimited is raising prices for Prime members, family plan users - Amazon Music Unlimited is increasing prices for Prime members and customers on the family plan, Amazon revealed on a FAQ page on its website. he Amazon Music Unlimited Individual Plan for Prime members is increasing from $8.99 to $9.99 per month, or $89 to $99 per year, while the Amazon Music Unlimited Family Plan is increasing from $15.99 to $16.99 per month, or $159 to $169 per year. The new prices will go into effect immediately for new customers and after September 19 for existing customers. Reference Link

10:07 EDT Chimerix announces data highlighting clinical efficacy of ONC201 treatment - Chimerix announced the publication of data in support of the Company's first-in-class small molecule imipridone, ONC201, as a treatment for H3 K27M-mutant diffuse midline gliomas in the peer-reviewed journal, Cancer Discovery, a journal of the American Association for Cancer Research. The manuscript titled, "Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways," reports survival analyses of 71 patients with H3 K27M-DMG treated with ONC201 which demonstrated promising results in a patient population with a poor prognosis and few treatment options. In addition to assessing clinical outcomes, the study corroborated mechanistic findings from laboratory models in samples from treated patients that demonstrated the ability of ONC201 to disrupt metabolic pathways and reverse the epigenetic consequence of the H3 K27M mutation. "The survival analyses published today in Cancer Discovery reported that ONC201 frontline treatment, administered post radiation therapy, demonstrated a statistically significant increase in mOS from diagnosis versus historical controls. These data are particularly relevant given that enrollment in the ongoing ACTION study occurs in a similar population. Additionally, these data further elucidate the underlying novel mechanism of action for ONC201 in a patient population which has very limited treatment options," said Mike Andriole, Chief Executive Officer of Chimerix. "While these results require validation in prospectively designed studies, such as the Phase 3 ACTION study, they nevertheless provide ongoing confidence and rationale for ONC201's monotherapy treatment effect and offer hope to the patients, families and caregivers facing this challenging and life-threatening cancer."

10:01 EDT BAE Systems awarded $14M contract from DARPA - The Defense Advanced Research Projects Agency has awarded BAE Systems' FAST Labs research and development organization a $14M contract for the Massive Cross Correlation program. BAE Systems will develop technology aimed at enabling the deployment of advanced signal processing and computation on a new smaller category of military platforms.

10:00 EDT Holley falls -11.8% - Holley is down -11.8%, or -86c to $6.46.

10:00 EDT H&R Block rises 7.1% - H&R Block is up 7.1%, or $2.50 to $37.85.

10:00 EDT Stride rises 9.0% - Stride is up 9.0%, or $3.43 to $41.72.

09:47 EDT ZIM Integrated falls -9.5% - ZIM Integrated is down -9.5%, or -$1.28 to $12.16.

09:47 EDT Coherent falls -23.5% - Coherent is down -23.5%, or -$11.04 to $35.97.

09:47 EDT AMTD Digital rises 9.6% - AMTD Digital is up 9.6%, or 57c to $6.47.

09:39 EDT Sacks Parente Golf Inc trading resumes

09:38 EDT Innoviz Technologies CEO 'confident' in continuing 'track record of executing' - Innoviz Technologies issued an open letter to its shareholders following its recently-completed underwritten public offering of ordinary shares. The letter said, "Following our successful capital raise last week, I want to offer additional color on the context and strategy behind the follow-on offering and what it accomplishes for our investors. Innoviz is currently participating in over five active RFQ sourcing processes, all with major automotive OEMs. While our previous cash balance was meaningful and gave us a substantial financial runway, the Board and management team felt that adding additional cash to the balance sheet would give us the best possible odds of securing further customer wins - an important step in the growth of our company. We believe we are in a once-in-a-lifetime market share capture window for the automotive LiDAR industry. We also believe that we have the technology that is needed to be a market leader, and now I am confident that we have the balance sheet that is needed as well. Oren Buskila, my fellow co-founder and our Chief R&D Officer, and I both invested in last week's follow-on offering, and Amichai Steimberg, our Chairman of the Board, increased his position in the company this week as well. This reflects our strong belief in the long-term success of the business and our confidence in our ability to execute on the many catalysts that lie ahead of us this year and next. Below I will outline a few key components of the Innoviz story to give you a better sense of our vision for the company and the tremendous opportunities that lie ahead. Winner Takes Most Market: At Innoviz, we believe the automotive LiDAR industry is ultimately going to be a winner-takes-most market. We expect that early leaders in the LiDAR industry will be able to create high barriers to entry versus new competitors, built upon technology leadership and volume-based cost advantages. Establishing an early leadership position can be an important component to long-term success. The Flywheel Effect: In the LiDAR industry, we believe that wins can lead to more wins. Securing additional awards in the near-term can further drive our technology leadership, capture additional NRE funding, and enhance volume-based cost advantages, leading to the potential for additional success thereafter. Significant Market Share Capture Window: On our first quarter earnings call this year I spoke about how several programs with major OEMs transitioned from RFIs to RFQs during the quarter, and with roughly half of our pipeline now in the RFQ phase, we are actively quoting on more than five RFQ's in parallel. OEMs are planning for these programs now and there are a slew of decisions that I expect to come in 2023-24. Since many of these programs are 8-10 years long, this is an opportunity to capture long-term market share in an industry where growth is poised to move quickly. Cash Runway: The cash secured by the recent capital raise extends our financial runway beyond the market share capture window, and if we secure additional awards, we can push our cash runway even further. NREs can Unlock Additional Cash Runway: Part of our strategy to become a Tier 1 automotive supplier was predicated on the fact that it is the only way to unlock meaningful non-recurring engineering bookings. We have previously disclosed that the typical NRE quote within our RFI/RFQ pipeline is for $20-40 million and we have some above the high end of that range, closer to the $60 million mark. These pre-production income streams represent a cash payment that can meaningfully offset our cash burn. Strong Track Record of Execution: In 2022, we hinted at a major new OEM customer and months later we delivered the Volkswagen Group. Coming into this year we hinted at a program expansion, and the next quarter we delivered the light commercial vehicle announcement. In the first quarter of 2023 we said we were working on a Minimum Risk Maneuver solution for a customer, and on our second quarter earnings call we announced the BMW B-sample with MRM and our AI compute module. And for the last year, we've been pointing to a 2023 start of production with the BMW 7 Series, and we began shipping the production units early in the third quarter. We want investors to recognize that we are delivering on the things that we say we are going to do. I am confident that we can continue our track record of executing. When combined, these factors point to a strong backdrop for Innoviz in the programs that we are actively competing on. I believe that the incremental capital that we raised will position us more favorably to deliver these wins. Thank you for your continued support and ongoing belief in the Innoviz mission."

09:34 EDT Cineverse secures global rights to 'Dog Whisperer with Cesar Milan' - Cineverse has secured global rights to one of the most popular animal shows: Dog Whisperer with Cesar Millan. Originally airing on the National Geographic Channel, this popular series starring Cesar Millan and everybody's favorite pet dogs, ran for 9 seasons with more than 160 episodes. Cineverse, which was previously known as Cinedigm, has secured rights to distribute the entire Dog Whisperer series across multiple digital platforms as part of the overall deal. This includes distribution via ad-supported video-on-demand, as well as the creation of a new free ad-supported streaming television channel -- the "Dog Whisperer" channel -- that will be made available on the Company's flagship Cineverse service, as well as third-party streaming platforms around the world.

09:29 EDT Performance Shipping regains compliance with Nasdaq minimum bid price rule - Performance Shipping announced that the Nasdaq Stock Market has confirmed that the Company has regained compliance with Nasdaq's minimum bid price requirements for continued listing on the Nasdaq Capital Market. Nasdaq's letter noted that, as a result of the closing bid price of the Company's common shares having been at $1.00 per share or greater for at least ten consecutive business days, from August 1, 2023 through August 14, 2023, the Company has regained compliance with Nasdaq's Listing Rule 5550(a)(2), and the matter is now closed.

09:14 EDT Longeveron says SEC declares rights offering effective - Longeveron announced that its registration statement previously filed with the Securities and Exchange Commission to conduct a tradable subscription rights offering has been declared effective, and that it has finalized the rights offering calendar. The rights offering is being made through a distribution of five tradable subscription rights to purchase shares of Class A common stock for each share of common stock and warrant to purchase common stock owned on the record date, at a $3.00 subscription price per share. The rights offering includes an over-subscription privilege, entitling each rights holder that exercises all of its basic subscription rights in full the ability to purchase additional shares of Class A common stock that remain unsubscribed at the expiration of the rights offering, subject to the availability and pro rata allocation of shares among those exercising this over-subscription privilege. The registration statement also covers the placement of unsubscribed shares of Class A common stock for an additional period of up to 45 days following expiration of the offering, as well as the potential resale of subscription rights by the Company's principal stockholders, directors and executive officers during the period for which the subscription rights may be transferred in accordance with the terms of the rights offering.

09:11 EDT EnWave signs technology evaluation, license option agreement with Moleciwl Cyf - EnWave Corporation announced that it has signed a Technology Evaluation and License Option Agreement with Moleciwl Cyf, a Welsh toll-manufacturing start-up that will provide value-added processing and drying services to fruit and vegetable growers across the United Kingdom. During the term of the Agreement, Moleciwl Cyf will lease a pilot-scale vacuum-microwave machine to facilitate in-house product development, and market-testing for domestically-grown dried fruit and vegetable products destined for snack and ingredient applications. If the technology evaluation is successful, the Agreement provides Moleciwl Cyf with the right to license EnWave's Radiant Energy Vacuum technology, the Company's proprietary vacuum-microwave platform, to process fruit and vegetable products in Wales.

09:10 EDT Immix announces additional NXC-201 AL Amyloidosis data to be presented - Immix Biopharma announced that additional NXC-201 clinical data for relapsed/refractory AL Amyloidosis has been selected for oral presentation at the 20th International Myeloma Society Annual Meeting to be held in Athens, Greece, September 27-30, 2023. "We are pleased to present additional clinical data in the NEXICART-1 clinical study evaluating NXC-201 in patients with relapsed/refractory light chain AL amyloidosis at the upcoming International Myeloma Society Annual Meeting in September," said Polina Stepensky, M.D., Director of the Hadassah Medical Organization's Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and NXC-201 principal study investigator. "We continue to make progress in this important indication, in the hope of providing patients with new treatment options."

09:08 EDT Nokia expands manufacturing in U.S. to fiber broadband optimal modules - Nokia announced that it is the first telecom vendor to manufacture fiber broadband optical modules in the U.S. for use in the Broadband Equity, Access and Deployment, BEAD, program. Partnering with Fabrinet, a global manufacturer of highly precise optical products, Nokia will produce multi-rate optical modules at Fabrinet's state-of-the-art facility in Santa Clara, California. Production will start in 2024 and brings additional high-tech jobs to the country. The announcement builds on Nokia's previous decision to produce fiber-optic broadband network electronic products in Kenosha, Wisconsin. Sandy Motley, President of Fixed Networks at Nokia, said: "Many in the industry have said that manufacturing optical modules in the U.S. was impossible. Today, we're proving it can be done. Working alongside the Department of Commerce and Fabrinet, we're excited to add optical modules to the list of technology solutions that will be produced here in the U.S. and become available to programs like BEAD which are so critical to bridging the digital divide."

09:07 EDT Natera: Prospera lung transplant assessment test granted Medicare coverage - Natera announced that it has received confirmation that its Prospera Lung donor-derived cfDNA, dd-cfDNA, transplant assessment test has met coverage requirements from the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services Program, MolDX. The MolDX technology assessment program has determined that Prospera Lung will be covered under the existing Medicare Local Coverage Determination for Molecular Testing for Solid Organ Allograft Rejection for use in the surveillance setting in lung transplant patients. Lung transplantation has a five-year survival rate of 59%, the lowest rate of all transplanted organs. Moreover, in the last 20 years, there has been limited improvement in recipient survival. "Medicare's decision enables broad access to the Prospera Lung test and represents a significant win for lung transplant patients and the field of transplant monitoring," said Bernie Tobin, general manager of organ health at Natera. "Prior to this decision, nearly 50 percent of the top 50 transplant centers have used Prospera Lung. We are encouraged by this momentum and gratified by the ongoing support from members of the transplant community who understand the clinical utility of dd-cfDNA testing and the critical benefits it can bring to patients."

09:06 EDT NaaS teams with Hyundai to boost EV charging services, business ventures - NaaS (NAAS) combined with the world's third-largest Automaker, Hyundai Motor (HYMTF), to develop efficient charging management service for Hyundai car owners. Furthermore, two parties will empower potential EV charging businesses via partnership. The partnership between NaaS and Chinese entity of Hyundai Motor Group made charging services and solutions for order management to be equipped with Hyundai models. Hyundai car owners can check charging and charger installation status in real-time through a smart service App or at the center console. "Charging facilities as a significant component of new infrastructure serves a crucial role in improving the penetration of EVs," Wang Yang, Founder and CEO of NaaS stated, "partnered with new energy industry chain players, NaaS will engage users in faster, easier and more cost-effective charging service, and work with Hyundai Motor Group to spur the upgrade of charging services."

09:05 EDT LPL Financial: Andrew Hayek joins broker-dealer, RIA, custodial platforms - LPL Financial LLC announced that financial advisor Andrew Hayek has joined LPL Financial's broker-dealer, RIA and custodial platforms, aligned with existing firm Bluestone Wealth Partners. Hayek reported having served approximately $165 million in advisory, brokerage and retirement plan assets and joins LPL from JP Morgan Securities.

09:01 EDT Target says beginning to see recovery in consumer confidence - Says facing multiple headwinds. Says guests are facing multiple challenges. Says hopeful conditions can improve with time. Says has much leaner inventory. Says beginning to see a recovery in consumer confidence. Says pleased with results so far in first 10 days of August. Comments taken from Q2 earnings conference call.

08:43 EDT Jaguar Health announces results of survey of neurologists, patients, caregivers - Napo Pharmaceuticals announced that the results of a Napo-sponsored survey of 15 US neurologists who treat patients with amyotrophic lateral sclerosis, and the results of a corresponding Napo-sponsored survey of 15 US individuals who are either ALS patients or caregivers of an ALS patient, indicate that the burden of diarrhea associated with a commonly used treatment for this rare progressive neurodegenerative disease may be higher than previously understood. Napo focuses on essential supportive care and management of neglected toxicities in multiple complicated disease states. Highlights of the survey of neurologists: 87% reported the severity of diarrhea associated with the ALS drug as moderate to severe. Over half reported stopping a patient's use of the ALS drug due to diarrhea. 13% reported that ALS patients in their care had been hospitalized or required other medical interventions due to diarrhea while taking the ALS drug. 79% reported the impact of diarrhea on the quality of life of patients on the ALS drug as moderate to severe. 40% reported that patients in their care had skipped doses of the ALS drug due to diarrhea. Highlights of the survey of ALS patients & caregivers: 93% of participants rated the severity of the diarrhea as moderate or higher. 27% rated it severe. Similarly, 93% rated the impact on quality of life as moderate or greater. 40% rated the impact severe. Almost half reported stopping the ALS drug due to diarrhea. 40% reported requiring hospitalization or some other medical intervention due to diarrhea. 67% of participants said diarrhea was experienced throughout the time on the ALS drug, with 20% reporting that symptoms increased over time. Slightly less than half took any medications to manage their diarrhea.

08:40 EDT Murphy Canyon Acquisition says SEC declares Form-S4 registration effective - Murphy Canyon Acquisition announced that its proxy statement/registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission on May 12, 2023, as amended, was declared effective by the SEC on August 11, 2023. The Registration Statement was filed in connection with the proposed business combination between Murphy Canyon and Conduit Pharmaceuticals previously announced on November 8, 2022. Conduit is a disease agnostic life science company providing an efficient model for compound development. Formed in 2019, Conduit is a departure from the traditional big pharma/biotech business model whereby, typically companies shepherd their assets through regulatory approval, Conduit acquires assets that are Phase II-ready and then seeks an exit through third-party license deals following successful clinical trials. Conduit is led by a highly experienced team of pharmaceutical executives, including Dr. David Tapolczay and Dr. Freda Lewis-Hall, established to fund the development of clinical molecules licensed from major pharmaceutical companies. Dr. David Tapolczay will remain Conduit's CEO, and Dr. Freda Lewis-Hall will be the Chair of the Board of Directors upon closing of the business combination. Murphy Canyon has scheduled a special meeting of its stockholders to seek approval and adoption of the Business Combination Agreement and the transactions contemplated thereby, and other related matters, a key milestone in the business combination process. The Murphy Canyon special meeting of stockholders will be held on September 7, 2023, at 10:00 am Eastern Time. Murphy Canyon's common stockholders of record as of the close of business on August 2, 2023, are entitled to receive notice of, to vote, and have their votes counted at the special meeting and any adjournment thereof. The closing of the Transaction, which is expected to occur in the third quarter of 2023, is subject to approval by Murphy Canyon's stockholders and the other closing conditions set forth in the definitive Business Combination Agreement. Upon closing, the combined company will be called "Conduit Pharmaceuticals Inc.", and its common stock and warrants are expected to be listed on The Nasdaq Capital Market under the symbols "CDT" and "CDTTW," respectively.

08:38 EDT BriaCell awarded NCI grant to advance Bria-OTS immunotherapy - BriaCell Therapeutics announced that the National Cancer Institute, the United States federal government's principal agency for cancer research and training, has awarded the Company a research grant to advance its platform of personalized off-the-shelf immunotherapies for cancer. The grant award of non-dilutive funds is titled "An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors". The Company intends to use the funds for the development of Bria-OTS, BriaCell's novel personalized off-the-shelf immunotherapies for advanced metastatic breast cancer, prostate cancer, lung cancer, and melanoma.

08:36 EDT ESGL Holdings expands waste transformation capacity - ESGL Holdings announced an advancement in waste management technology with the successful doubling of its G-2 Thermal System's capacity. This achievement signifies ESGL's unwavering commitment to environmental sustainability and circular economy practices. The G-2 Thermal System, renowned for its proprietary design, has now been upgraded to address the escalating demands of unrecyclable industrial sludge management, especially from Wafer Fabs and other key industries.

08:35 EDT Evolv expands partnership with South Carolina's Florence Schools - Evolv Technology has expanded its partnership with South Carolina's Florence Schools. In 2019, the largest school district in Florence County, Florence, became the second school district in the country to implement Evolv's technology. It has since expanded its use to 23 Evolv Express systems across eight schools.

08:33 EDT Syla Technologies intends to establish employee stock purchase plan - SYLA Technologies intends to establish an Employee Stock Purchase Plan as part of its efforts to enhance corporate value and provide employee benefits. SYLA intends to establish such a plan due to the many benefits to both the Company and its employees. These benefits include employee engagement in partial ownership in the Company, retention and recruitment purposes, interest alignment between corporation and employee, and importantly the ability for employees to gain greater wealth accumulation opportunities through the Company. The Company also intends to provide a subsidy for purchases.

08:32 EDT LiveOne's Slacker Radio adds 238K paid members since April - LiveOne continues to break multiple membership records. Contributing to this surge are new memberships associated with Tesla, LiveOne's largest customer.

08:31 EDT Nocturne Acquisition files registration statement on Form S-4 - Nocturne Acquisition Corporation announced the submission via Edgar, the U.S. Securities and Exchange Commission's online portal, for filing of a registration statement on Form S-4 with the SEC, which includes a preliminary proxy statement/prospectus in connection with the proposed business combination with Cognos Therapeutics, a medical technology company focused on developing unique, radically advanced devices for the treatment of neurological diseases including brain and spinal cancers, and degenerative neurological conditions, epilepsy, and stroke. The Registration Statement contains a preliminary proxy statement/prospectus in connection with the previously announced Business Combination between Nocturne and Cognos. While the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about Nocturne and Cognos, as well as the proposed business combination. On December 30, 2022, Nocturne and Cognos entered into an Agreement and Plan of Merger and Reorganization. The Business Combination is expected to close in the fourth quarter of 2023 and has been unanimously approved by the boards of directors of Cognos and it is subject to a number of closing conditions, including the Registration Statement being declared effective by the SEC, the approval of the transaction by Nocturne's shareholders and a number of other customary conditions. The combined company is expected to be renamed Cognos Therapeutics Holdings, Inc. and is expected to trade on the Nasdaq under the symbol "COGN." Prior to closing of the proposed transaction, Nocturne shares will continue to trade on the Nasdaq under the "MBTC" symbol.

08:27 EDT Alpha Teknova appoints Demski as new board member - Alpha Teknova announced the appointment of Martha Demski to its Board of Directors, bringing to the Board more than 35 years of experience in corporate leadership and life sciences business and financial strategies. She will replace Robert McNamara, who has served on the Board since Teknova's IPO in 2021 and has announced his intention to step down to pursue other opportunities. Both Demski's appointment and McNamara's resignation will be effective on August 31, 2023. Demski was elected to serve on the Company's Board as an independent Director at its recent quarterly meeting on August 8, 2023. In addition to her role as Director, she will serve as chair of the Board's Audit Committee and will join its Compensation Committee as a member.

08:26 EDT Nano Dimension sends letter to shareholders, releases video - Nano Dimension sent a letter to shareholders in connection with the Company's upcoming 2023 Annual General Meeting of Shareholders. Nano's Board urges shareholders to protect their investment and the future of the Company by voting today "FOR" ALL of Nano's highly qualified nominees. The Annual Meeting will be held on Thursday, September 7th, at 8:00 a.m. ET. In connection with the Annual Meeting and its letter to shareholders, the Company also released a video from CEO and Chairman, Yoav Stern, in which he highlights Nano's strong performance and the significant long-term value creation opportunity, while underscoring Murchinson's lack of a strategic plan and aim to gain access to the Company's cash reserves at the expense of other shareholders. The letter said, "You face a stark choice as a Nano shareholder. You can either: Vote for ALL of Nano's highly qualified directors, allowing our Board to continue executing on our strategic plan that is building significant long-term value for all Nano shareholders; - OR - Vote for the nominees of a self-interested hedge fund that have no understanding of our business, no strategic plan and likely intend to liquidate Nano's cash assets at the expense of other shareholders."

08:23 EDT Comera Life Sciences announces publication of study on caffeine - Comera Life Sciences announced the peer-reviewed publication of preclinical data in the Journal of Pharmaceutical Sciences, which provide further evidence of caffeine's viscosity reducing capabilities and support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies. These studies aimed to assess the pharmacokinetic characteristics of caffeine and its influence on the PK behavior of a representative monoclonal antibody ipilimumab. The outcomes show rapid SQ absorption and elimination of caffeine, regardless of whether it was administered alone or in conjunction with the monoclonal antibody. Notably, caffeine exhibited no impact on the PK profiles of ipilimumab with SQ administration. "Comera continues to innovate on the delivery of biologic medicines and this publication reflects our extensive expertise in solving some of the most challenging problems in protein engineering," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. "These insights bring us closer to delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines. We look forward to continuing the development of caffeine as a viscosity reducing agent for subcutaneous monoclonal antibody formulations, while also embarking on the expansion of our computational modeling tools to potentially include cutting-edge AI capabilities."

08:20 EDT Mustang announces first data from ongoing multicenter Phase 1/2 trial of MB-106 - Mustang Bio announced the first data from the indolent lymphoma cohort of the Company's ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia, demonstrating clinical responses as well as safety and efficacy consistent with the ongoing Phase 1/2 clinical trial taking place at Fred Hutchinson Cancer Center. Initial data were presented by Mazyar Shadman, M.D., M.P.H., Study Chair, Associate Professor and physician at Fred Hutch and University of Washington, at the 5th International Workshop on CAR-T and Immunotherapies. The multicenter study data show clinical responses in four of four patients with relapsed or refractory indolent NHL at the starting dose of 3.3 x 106 CAR-T cells/kg, a dose comparable to that employed for the majority of the indolent lymphoma patients in the Fred Hutch trial. The multicenter data also show persistence of CAR-T cells at 6+ months and favorable safety data with only Grade 1 cytokine release syndrome reported to date. Two patients with follicular lymphoma had complete response, CR, by both PET-CT and bone marrow, one of whom had been previously treated with a CD19-directed CAR-T. A third patient, with a diagnosis of Waldenstrom macroglobulinemia, who had nine prior treatments and high disease burden, achieved complete metabolic response by PET-CT, morphologic clearance of lymphoma in bone marrow, and resolution of the IgM monoclonal protein. The fourth patient, with a diagnosis of hairy cell leukemia variant, who had been heavily transfusion dependent, continues to have stable disease with decreased disease in his bone marrow and achieved complete transfusion independence, which is ongoing at 6+ months. Dr. Shadman also presented data from the ongoing Fred Hutch Phase 1/2 clinical trial, specific to two B-NHL cohorts, follicular lymphoma and WM. In the FL data cohort, an overall response rate of 95% was seen, of which 80% of patients experienced a CR, and 15% had a partial response. The CR patients include a patient who was previously treated with a CD19-directed CAR-T cell therapy. Of the six patients who experienced CRS, only one had Grade 2. Ten patients continue to experience CR for more than 10 months, four patients have experienced CR for more than two years, and the first patient enrolled has sustained CR for more than 3 years. In the WM cohort, all of whom had received prior Bruton tyrosine kinase inhibitor, two patients experienced CR, one of whom continues to be in CR at more than 22 months.

08:18 EDT Silicon Motion terminates merger deal with MaxLinear, intends to pursue damages - Silicon Motion Technology (SIMO) issued a written notice to MaxLinear, Inc. (MXL), terminating the Agreement and Plan of Merger between the parties dated as of May 5, 2022 The company said, "Silicon Motion's position is that MaxLinear's Willful and Material Breaches of the Merger Agreement prevented the merger from being completed by August 7, 2023 Silicon Motion reserves all of its contractual, legal, equitable, and other rights under the Merger Agreement and otherwise, including but not limited to the right to hold MaxLinear liable for substantial money damages, well in excess of the termination fee as provided in the Merger Agreement, suffered by Silicon Motion as a result of MaxLinear's Willful and Material Breaches of the Merger Agreement. Pursuant to Section 7.1(d) of the Merger Agreement, the Company has the right to terminate the Merger Agreement if the completion of the merger contemplated by the Merger Agreement did not occur on or before the "Outside Date"." Tim Gardner, partner of Weil, Gotshal & Manges LLP, counsel to the Company, commented as follows: MaxLinear's purported termination of its Merger Agreement with Silicon Motion will be the subject of an arbitration for substantial damages in the Singapore International Arbitration Centre, as provided under the parties' agreement. MaxLinear's professed reason for terminating the agreement - that Silicon Motion suffered a Material Adverse Effect - is a pretext and has been rejected in case after case under Delaware law, which governs the MAE issue, where buyers have sought to back out of merger agreements at the eleventh hour. The damages Silicon Motion will seek to recover far exceed the termination fee."

08:16 EDT Soleno Therapeutics appoints Matthew Pauls to board of directors - Soleno Therapeutics announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023. Since 2020, Mr. Pauls has served as Chair of the Board of Directors and Chief Executive Officer of Savara, Inc., a biopharmaceutical company focused on rare respiratory diseases.

08:15 EDT Cidara Therapeutics appoints Nicole Davarpanah as VP, translational R&D - Cidara Therapeutics announced the appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development. In this position, Dr. Davarpanah will lead the company's oncology efforts, focusing on the strategy for preclinical, translational, and early clinical development activities to identify and advance drug candidates through human proof-of-concept studies. Dr. Davarpanah joins Cidara from Genentech/Roche where she most recently served as Clinical and Translational Lead in Oncology.

08:14 EDT Mangoceuticals announces commercial launch of second Mango ED product - Mangoceuticals announced the official commercial launch of its second Mango ED product, which leverages the Company's existing custom compound alongside Sildenafil, the active ingredient found in Viagra. Interested consumers can now proceed through the Company's telemedicine platform and select either a Sildenafil-based Mango or the Company's original Tadalafil-based Mango ED product, which leverages the active ingredient found in Cialis. Both the Sildenafil and Tadalafil-based Mango ED products are compounded with Oxytocin and L-Arginine in a tasty Mango-flavored, rapid dissolve tablet and individually packaged in a master pack of six tablets per package.

08:12 EDT Gentherm appoints Vishnu Sundaram as CTO - Gentherm (THRM) announced that Vishnu Sundaram will join the Company's leadership team as Senior Vice President and Chief Technology Officer on September 5, 2023. In this role, Sundaram will lead Gentherm's technology strategy, advanced product engineering, longer term R&D, and the Company's partnership ecosystem to continue Gentherm's heritage of introducing innovations in Climate Comfort, Pneumatic Lumbar and Massage, Battery Performance Solutions, Electronics and Software systems, and Patient Thermal Solutions. Sundaram will report to Gentherm's President and CEO, Phil Eyler. Sundaram comes to Gentherm from Stellantis(STLA), where he was the Senior Vice President, Head of Cockpit Connected Services

08:11 EDT Stock Yards names Shannon Budnick as director, Wealth Management & Trust Group - Stock Yards Bancorp announced that Kathy Thompson will retire from her position as Senior Executive VP, Director of Wealth Management & Trust Group, effective January 2, 2024. Effective January 3, 2024, Shannon Budnick, currently Senior VP and Managing Director of Investments, will succeed Ms. Thompson in the position of Executive VP, Director of Wealth Management & Trust Group. Ms. Budnick joined Stock Yards Bank & Trust in 2007 as a Wealth Advisor. She was named Senior VP in 2013 and Managing Director of Investments in 2015 and has been a key contributor to the Wealth Management & Trust's growth and success.

08:09 EDT Seagen says 'OS, data, a secondary endpoint, are not yet mature' - Overall survival, OS, data, a secondary endpoint, are not yet mature. Discontinuations due to adverse events were more common in the combination arm of the trial, but no new safety signals emerged for the combination. "We are encouraged by these results for TUKYSA in combination with Kadcyla in metastatic HER2-positive breast cancer, including in patients with brain metastases," said Roger Dansey, President of Research and Development and Chief Medical Officer at Seagen. "We plan to present the HER2CLIMB-02 data at an upcoming medical meeting and discuss the results with the FDA."

08:07 EDT Nokia, Eastlink enter multiyear deal to enhance 5G network - Nokia and Eastlink announced a multi-year strategic access network partnership that will further modernize Eastlink's mobile network. Using Nokia's comprehensive, energy efficient AirScale portfolio, including 5G RAN, Eastlink will enhance its mobile experience with faster speeds, increased performance, and greater network capacity. The partnership includes new site expansion and existing site upgrades. The first site using Nokia technology is expected to go live in August.

08:06 EDT Taoping regains compliance with NASDAQ listing rules - Taoping announced that on August 15, it received notification from The Nasdaq Stock Market confirming the Company has cured the bid price deficiency, and that the Company has regained compliance with Listing Rule 5550. Accordingly, this matter is now closed.

08:05 EDT Duos Technologies Group reports 13 operational Railcar Inspection Portals - Duos Technologies Group announced that the Company now has 13 Railcar Inspection Portals in operation with four major railroads. The Company also recently reported that its RIP technology across those same 13 portals has performed over 3.8 million comprehensive railcar scans through the first half of 2023. This metric encompasses all railcars scanned at locations across the U.S., Canada, and Mexico.

08:05 EDT MEI Pharma doses first patient in ME-344 study - MEI Pharma announced the dosing of the first patient in a Phase 1b study evaluating ME-344 in combination with bevacizumab in patients with previously treated metastatic colorectal cancer.

08:04 EDT Energy Transfer LP to acquire Crestwood Equity in $7.1B all-equity transaction - Energy Transfer LP (ET) and Crestwood Equity (CEQP) announced that the parties have entered into a definitive merger agreement pursuant to which Energy Transfer will acquire Crestwood in an all-equity transaction valued at approximately $7.1B, including the assumption of $3.3Bof debt, based on the closing price on August 15. Under the terms of the agreement, Crestwood common unitholders will receive 2.07 Energy Transfer common units for each Crestwood common unit. The transaction is expected to close in the fourth quarter, subject to the approval of Crestwood's unitholders, regulatory approvals, and other customary closing conditions. Upon closing, Crestwood common unitholders are expected to own approximately 6.5% of Energy Transfer's outstanding common units. Crestwood's system includes gathering and processing assets located in the Williston, Delaware and Powder River basins, including approximately 2B cubic feet per day of gas gathering capacity, 1.4B cubic feet per day of gas processing capacity and 340 thousand barrels per day of crude gathering capacity. The transaction is expected to be immediately accretive to distributable cash flow per unit as well as neutral to Energy Transfer's leverage metrics upon closing. Energy Transfer also expects to achieve at least $40M of annual run-rate cost synergies before additional benefits of financial and commercial opportunities.

07:55 EDT Snail announces early access launch of 'Survivor Mercs' - Snail announced Wolpertinger Games, a newly contracted independent studio, aims to launch the early access of Survivor Mercs on Thursday September 14th, 2023, on Steam and Steam Deck. Survivor Mercs is a rogue-lite action game that blends the bullet-heaven and extraction shooter genre for a challenging single-player experience where no two gameplay runs are alike. Players assume the role of the Commander of an elite Mercs squad, battling against a formidable mega-corporation's private robot army on procedurally generated battlefields.

07:36 EDT iSpecimen announces enhanced propriety of its Marketplace platform - iSpecimen announced that the Company has enhanced its proprietary Marketplace platform to streamline biospecimen matchmaking for researchers and providers. The platform's new capabilities enable iSpecimen's Marketplace to efficiently collect and store the most up-to-date data from providers for fulfilling researcher orders at a lower cost. "iSpecimen's goal is to quickly give researchers access to the precise samples that they need to advance their work," said Tracy Curley, iSpecimen's CEO. "Our Marketplace's new capabilities will expand the breadth of specimen types that the platform provides by retrieving the most up-to-date information on biospecimen and collection capabilities from providers in our network. As matching biospecimen supply to research demand is the foundation of our business, we are committed to continuing to improve our technology to become an even better partner to researchers and providers."

07:35 EDT Mullen announces debut of ultra-high-performance FIVE RS demonstrator - Mullen Automotive announces the debut of the ultra-high-performance Mullen FIVE RS EV Crossover. The RS will be featured on the upcoming "Strikingly Different" EV tour kicking off on Aug. 20, 2023, in Austin, Texas. The Mullen FIVE RS is an ultra-high-performance EV featuring a top speed of 200 mph and acceleration from 0-60 mph in under 2 seconds. Equipped with 800-volt architecture, all-wheel drive, a two-speed gearbox, and over 1,100 horsepower, the vehicle has a performance-oriented suspension and massive 325/35R21 front and rear tires. "I want to encourage shareholders to continue sharing thoughts and opinions with Mullen, and remember we are working together to achieve great things, including pushing the boundaries of EV performance and electrifying the world," said David Michery, CEO and chairman of Mullen Automotive.

07:33 EDT Labrador Gold announces results from prospecting at Appleton Fault Zone - Labrador Gold announced results from recent prospecting along the highly prospective Appleton Fault Zone at its 100% owned Kingsway Project. Recent prospecting between Big Vein and Golden Glove near the southern property boundary has located a new gold showing, the Knobby occurrence. Grab samples from quartz vein outcrops returned gold values from below detection to 30.58 g/t including samples grading 0.4g/t, 2.7g/t and 29.19 g/t Au. Three parallel veins were observed and have been traced along an east-west strike for approximately 200 metres. Stibnite mineralization was observed associated with the quartz veining. This is the first indication of gold mineralization along the Appleton Fault Zone between Big Vein and Golden Glove, an area that has seen little work to date. "Today's results of high-grade, surface gold mineralization in quartz vein outcrops between Big Vein and Golden Glove is very encouraging for the prospectivity of this 3-kilometre section of the Appleton Fault Zone," said Roger Moss, President and CEO of Labrador Gold Corp. "This is an area that we have prioritized for drilling in the latter part of this year once we complete an ongoing ground magnetic/VLF survey and receive the necessary permits. We are excited by the discovery of the Knobby occurrence which is reminiscent of our initial discovery of Big Vein by prospecting almost three years ago."

07:31 EDT Vivos Therapeutics reschedules Q2 conference call - Vivos Therapeutics announced that the Company intends to release its second quarter 2023 financial results after market close today, Wednesday, August 16, 2023. The Company will conduct a conference call today at 6:00 p.m to review the results and provide an overview of the Company's recent milestones and developments.

07:18 EDT Newcore Gold announces update of its Enchi Gold Project in Ghana - Newcore Gold announces an update on exploration and development activities underway at the Company's 100% owned Enchi Gold Project in Ghana. Diamond Drilling at the Nyam Gold Deposit, targeting high-grade mineralization in the upper portions of the sulphide mineralization, intersected 3.28 grams per tonne gold over 11.0 metres, within a broader zone of 1.58 g/t Au over 26.3 m. Luke Alexander, President and CEO of Newcore stated, "We continue to advance and de-risk the development of our Enchi Gold Project in Ghana. Recently completed metallurgical testwork on sulphide mineralization at Nyam has confirmed strong recoveries averaging 91.7%, continuing to highlight the longer-term potential for resource growth from higher-grade sulphide mineralization at depth. We look forward to continuing to advance the development of Enchi with additional metallurgical testwork as we prioritize targets for our next phase of drilling to commence later this year."

07:16 EDT Oxus Acquisition files registration statement on Form S-4 - Oxus Acquisition and Borealis Foods announced the filing of the registration statement on Form S-4 with the U.S. Securities and Exchange Commission, marking a significant advance in Oxus's proposed business combination with Borealis. This filing brings Oxus closer to realizing its goal of helping to address global food and nutritional challenges, in partnership with an innovative food technology company Borealis. The Oxus team has been led by CEO Kanat Mynzhanov and Non-Executive Chairman Kenges Rakishev. The Proposed Transaction is currently expected to be completed late in the fourth quarter of 2023.

07:13 EDT EyePoint reports inducement grants under Nasdaq listing rule - EyePoint Pharmaceuticals announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 8,500 shares of EyePoint Pharmaceuticals common stock to two new employees. The stock options were granted on August 15, 2023. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $14.19 per share, the closing price of EyePoint Pharmaceuticals' common stock on August 15, 2023. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee's continued service with EyePoint Pharmaceuticals through the applicable vesting dates.

07:12 EDT Strathspey Crown clarifies Form 4 filing for AEON Biopharma holdings - Strathspey Crown Holdings provided a clarifying statement regarding its Form 4 filing with the United States Securities and Exchange Commission made on August 14th concerning its holdings of AEON Biopharma, Inc. class A common stock. Strathspey Crown is a Limited Liability Company with hundreds of limited partners, a large contingent of whom chose to tender their membership units to the Company for repurchase in return for a direct holding in AEON and certain other securities previously held by Strathspey Crown. The Form 4 filed on August 14, 2023 reflected the transfer of an aggregate of 7,380,394 AEON shares to these limited partners. Strathspey Crown did not sell any AEON shares to the public as part of this transaction. All shares transferred to limited partners continue to be subject to restrictions on transfer under securities laws and a significant portion are also subject to a 12-month lockup expiring July 21, 2024 as provided in AEON's bylaws. Subsequent to the July 24th listing of AEON on the New York Stock Exchange American, Strathspey Crown filed a Schedule 13D and a Form 3 on July 31, 2023 reflecting receipt of the newly listed AEON shares. The Schedule 13D indicated that Strathspey Crown intended to distribute shares in the tender offer to its limited partners.

07:09 EDT Bluebird Bio: FDA advisory committee not scheduling meeting for lovo-cel - bluebird bio announced that the U.S. Food and Drug Administration FDA has communicated that an advisory committee meeting will not be scheduled for lovotibeglogene autotemcel lovo-cel . Lovo-cel is a potentially transformative one-time gene therapy for individuals living with sickle cell disease SCD with a proposed indication for patients ages 12 and older who have a history of vaso-occlusive events VOEs . The Agency previously accepted the lovo-cel Biologics Licensing Application BLA for Priority Review and set a Prescription Drug User Fee Act PDUFA goal date of December 20. "Lovo-cel is the most deeply studied gene therapy in development for sickle cell disease and represents the third lentiviral vector gene therapy that the Agency has reviewed from bluebird-giving us great confidence in the robustness and maturity of our BLA package," said Andrew Obenshain, chief executive officer, bluebird bio. "We remain focused on working with the Agency on its review in anticipation of a decision by the end of this year."..The FDA previously granted lovo-cel orphan drug designation, fast track designation, regenerative medicine advanced therapy RMAT designation, and rare pediatric disease designation.

07:08 EDT NFI Group to increase new vehicle production rates in 2H23 - NFI anticipates positive improvements to revenue, gross profit, Adjusted EBITDA and Free Cash Flow, reduction in net loss, and improvement in ROIC as it delivers on its backlog, and benefits from record government investments in public transportation, and growing demand for its buses, coaches, parts and Infrastructure SolutionsTM services. Market demand is evident through the high volume of active bus and motor coach procurements in both North America and international markets. As of 2023 Q2, the Company's North American active bids remained high at 10,054 EUs. This bid activity is expected to drive additional backlog growth in the second half of 2023 and throughout 2024. The current five-year forecasted demand within the Company's North American bid universe is also strong at 21,569 EUs, and, when combined with active bids, provides a record Total Bid Universe of 31,623 EUs. In addition to the increased numbers of bids for ZEBs, the number of EUs per bid has increased, as transit agencies are progressing from pilot or trials to more active deployment and operation of ZEB fleets. NFI expects active ZEB bids to remain high through the coming years based on strong government funding levels. While certain supply chain challenges continue, and have impacted NFI's operating and financial performance, the Company has seen signs of significant improvement in the first half of 2023. The number of moderate and high risk suppliers within NFI's supply base has decreased, and, when combined with actions taken by NFI, on-time supplier delivery performance has improved, supporting expected increases to 2023 production volumes. Higher production allows NFI to absorb less fixed overhead on a per unit basis. NFI is maintaining its plan to increase new vehicle production rates in the second half of 2023, subject to continued and sustained supply performance and anticipates it will hire approximately 100 additional direct labour team members before the end of 2023. This will be a phased approach with gradual headcount additions throughout the second half of the year driving improvements to new vehicle starts and deliveries. NFI anticipates that it will experience some temporary production inefficiencies as it ramps-up production of new vehicles. Gross margins and other profitability metrics are expected to improve as NFI increases production rates, delivers more vehicles, and completes the remaining inflation impacted legacy contracts, originally bid in 2020 and 2021, in 2023. The Company has experienced signs of inflation easing during the first half of 2023 and anticipates that newer contracts in NFI's backlog now reflect appropriate, inflation-adjusted pricing.

07:07 EDT NFI Group continues to advance comprehensive refinancing plan - The Company continues to advance its comprehensive refinancing plan, and today announced that as part of that plan it has entered into subscription agreements with a leading global asset manager whereby certain funds managed and/or advised by the Investor have agreed to subscribe for and purchase from the Company an aggregate of 5,000,000 Shares, on a private placement basis, at a subscription price of C$10.10 per share, for aggregate gross proceeds to NFI of C$50,500,000.The net proceeds from the August Private Placement will be used by the Company to repay outstanding indebtedness under NFI's existing credit facilities and for working capital and general corporate purposes. The Shares to be issued in the August Private Placement will be subject to a four-month hold period in accordance with applicable securities law rules. Completion of the August Private Placement is subject to customary conditions, approval by the Toronto Stock Exchange, and is conditional upon the concurrent completion of the other elements of the Refinancing Plan. Following completion of the Refinancing Plan, NFI expects that it will have 118.9 million Shares outstanding. NFI expects to close all elements of the Refinancing Plan concurrently prior to August 31, 2023. Based on the expected proceeds from the August Private Placement, NFI intends to lower the gross proceeds from its proposed second lien debt financing from $200 million to approximately $180 million. This is expected to generate annual interest savings of up to $2.9 million per annum. Upon close of the Refinancing Plan, the Company will permanently reduce capacity under its Secured Facilities by $250 million, and receive additional liquidity of approximately $135 to $140 million as the Company will lower carrying balances on its revolving credit facilities and increase cash on-hand.

07:06 EDT Horizon Robotics forms strategic partnership with Aptiv, Wind River - Horizon Robotics recently formed a strategic partnership with Aptiv and its subsidiary Wind River in China. Aptiv is a global technology company focused on making mobility safer, greener and more connected, and Wind River is a global leader in delivering software for mission-critical intelligent systems. The collaboration marks Aptiv's first partnership with a Chinese domestic supplier of auto grade computing solutions for ADAS and automated driving. The partners aim to empower and revolutionize the automotive industry in China by harnessing their unique expertise, ultimately providing Chinese drivers and passengers with a safer, more convenient and enjoyable journey. Under the agreement, Horizon Robotics will work with Aptiv and Wind River to develop fully integrated hardware and software solutions tailored for civil automakers in China. Horizon's self-developed Journey series computing solutions will be well complemented by Wind River's portfolio, including VxWorks real-time operating system, Wind River Helix Virtualization Platform, Wind River Linux and Wind River Studio, to power the next-generation of software-defined vehicles.

07:02 EDT Canadian Solar unit awarded 20-year tolling agreement with APS - Canadian Solar announced that Recurrent Energy, its wholly-owned subsidiary for global project development and power services, secured a 20-year tolling agreement with Arizona Public Service Company for Papago Storage, a 1,200 MWh energy storage project under development in Maricopa County, Arizona. Construction of Papago Storage is expected to begin in the third quarter of 2024 with planned commercial operation in the second quarter of 2025. Once operational, Papago Storage will be the largest standalone energy storage project in Arizona. The tolling agreement award for Papago Storage comes as Arizona, and states across the U.S., face record electricity demand. The energy storage capacity provided by Papago Storage will complement Arizona's growing solar energy capacity and will also help the state meet surging electricity demand.

06:41 EDT HF Sinclair announces $1B share repurchase program - HF Sinclair announced its Board of Directors has authorized a $1B share repurchase program. This authorization replaces all existing share repurchase authorizations, of which there was approximately $5M remaining under the company's prior $1B share repurchase program authorized in September 2022. This share repurchase program may be discontinued at any time by the Board of Directors.

06:31 EDT HF Sinclair, Holly Energy Partners announce definitive merger agreement - HF Sinclair (DINO) and Holly Energy Partners (HEP) announced today that they have entered into a definitive merger agreement for HF Sinclair to acquire all of the outstanding common units of HEP not owned by HF Sinclair or its affiliates in exchange for a combination of common stock, par value $0.01 per share, of HF Sinclair and cash. The agreement provides for consideration of both stock and cash in which each holder of Common Units would receive a combination of 0.315 shares of Common Stock and $4.00 in cash, without interest, for each publicly held Common Unit. The Proposed Transaction consideration represents an approximate 2% premium to the closing price of HEP's Common Units as of August 15, 2023. HF Sinclair's Chief Executive Officer and President, Tim Go, commented, "We are pleased to announce this strategic transaction which we believe simplifies our corporate structure, reduces costs and further supports the integration and optimization of our portfolio. We expect the transaction to be accretive to earnings per share and available free cash flow within the first twelve months, further supporting our capital allocation strategy of returning excess cash to shareholders." Upon closing of the Proposed Transaction, the Partnership will be a wholly owned subsidiary of HF Sinclair and will no longer be a publicly traded partnership. The Proposed Transaction is expected to close in the fourth quarter of 2023, subject to the approval of HF Sinclair stockholders and HEP unitholders and the satisfaction of certain customary closing conditions.

06:02 EDT Eyenovia and Formosa sign licensing agreement for APP13007 - Formosa Pharmaceuticals announced that the company has entered into a licensing agreement with Eyenovia, whereby Eyenovia obtains exclusive U.S. rights for the commercialization of APP13007, or clobetasol propionate ophthalmic nanosuspension, for the treatment of inflammation and pain following ocular surgery. APP13007 is currently under review by the FDA and has been assigned a Prescription Drug User Fee Act, or PDUFA, date of March 4, 2024. The total deal package, including upfront payment and development and sales milestones, has a value of $86 million dollars, with additional considerations throughout the term of the agreement. APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT nanoparticle formulation platform.

05:12 EDT Motorola Solutions equips police officers in German state with body cameras - Motorola Solutions announced that the company signed a contract with the Ministry of the Interior of the German federal state of Saxony-Anhalt to deploy VB400 body-worn cameras including VideoManager evidence management software to the state's police officers. The roll out of the new body-worn camera solutions to the City of Stendal Police Inspectorate and the police academy in Aschersleben marks the beginning of a wider deployment to nearly all operational frontline teams in Saxony-Anhalt. The cameras will be implemented to help officers to de-escalate potentially dangerous situations and increase safety and transparency on the front line. Motorola Solutions' rugged VB400 body-worn cameras will be rolled out alongside VideoManager evidence management software, enabling officers to easily upload and securely store and manage video footage, organized with time, date and location as part of the force's existing daily workflows. The cameras offer a pre-recording capability to help ensure incidents are captured from the start, and are equipped with an extended battery life that lasts beyond a shift with up to 12 hours of recording. The new body-worn cameras can be integrated with a broad range of sensors, such as Holster Aware which automatically activates video recording and live-streams footage if an officer draws a weapon.

05:06 EDT NaaS, Hyundai Motor announce EV charging service partnership - NaaS (NAAS) and Hyundai Motor (HYMTF) announced the companies will develop an efficient charging management service for Hyundai car owners. Furthermore, the two parties will empower potential EV charging businesses via partnership. The partnership between NaaS and Chinese entity of Hyundai Motor Group made charging services and solutions for order management to be equipped with Hyundai models. Hyundai car owners can check charging and charger installation status in real-time through a smart service App or at the center console.